An implantable device that combines a drug-delivery channel with miniature ultrasound transducers helped molecules spread farther in a tissue model and in mouse brains, according to an October 26 report by MIT News’ Anne Trafton. The findings point to a possible way to improve local drug delivery in the brain, but they do not show that the device prevents tumors from returning or benefits patients.
The device, called LUCID, was designed by researchers at MIT. Its name stands for Long-term Ultrasound-enhanced Convective Injection Device. The team’s goal is to address a challenge in treating glioblastoma, an aggressive brain cancer: surgery can leave cancer cells behind, and the tumor often recurs. Drugs delivered through the bloodstream can also have difficulty reaching the brain because of the blood-brain barrier.
LUCID brings together a fluid-delivery channel and an array of 24 miniature ultrasound transducers. The channel is 3D-printed onto the array, which generates ultrasound near the channel’s tip. The researchers describe the implant as flexible and about as thin as a sheet of cardstock. Its reservoir holds about 100 microliters of fluid, supplied by a passive osmotic pump. Ultrasound can be controlled wirelessly through Bluetooth, and the device has a wirelessly rechargeable battery.
The team tested ultrasound-assisted delivery in two settings. In a gel-like “tissue phantom” engineered to mimic human tissue, molecules spread farther with ultrasound than without it. In mice, the researchers delivered an MRI contrast agent. It spread farther through the brain when the ultrasound array was active. The mouse test therefore measured the distribution of a contrast agent, not whether a cancer drug could eliminate tumor cells.
The approach builds on earlier research, as described in Trafton’s report. Ultrasound-generated mechanical motion can create flows that help molecules travel farther, and ultrasound may temporarily increase the permeability of the blood-brain barrier. The reported LUCID tests support wider distribution in the tested settings; they do not establish that the device safely or reliably delivers a therapy across that barrier in people.
Wider local distribution could matter because a drug needs to reach cells around a tumor, not simply enter the brain. The researchers suggest that improving its spread in the target area might help therapy reach more remaining cancer cells and reduce exposure in other organs. That is a potential benefit, not an outcome demonstrated by the reported experiments. The described results do not measure tumor recurrence, patient survival, or clinical safety.
MIT associate professor Canan Dagdeviren is the study’s senior author. MIT graduate student Sarah Ornellas and Jason Hou, identified as a PhD ’26, are its lead authors. MIT News reports that the paper, “Long-term ultrasound-enhanced convective injection device for neural drug delivery,” appeared in the journal Device. The work is an early test of a prototype and a delivery concept; whether it can improve treatment remains an open question.
<a href="https://news.mit.edu/2026/implantable-device-uses-ultrasound-improve-drug-delivery-brain-1026">Source: MIT News report</a>